The Boston-based Institute for Clinical and Economic Review has released a new draft report in which the group stated that the prices for a newly-approved class of cholesterol lowering medications are far too expensive relative to their overall effectiveness.
The Boston-based Institute for Clinical and Economic Review has released a new draft report in which the group stated that the prices for a newly-approved class of cholesterol lowering medications are far too expensive relative to their overall effectiveness.
Share this Article
Recommended